MDRNA has appeared on the horizon as another RNAi-focused company hoping to make good on the promise of using RNA interference to develop safe and effective RNA-based therapeutics. As part of a shift in business focus, the 55-person Bothell, Wash.-based company changed its name this summer from Nastech to MDRNA. Run by CEO Michael French, MDRNA's goal is to develop novel compounds and unique drug delivery techniques, aiming to get its lead candidate into phase I clinical trials by the end of 2009.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.